Cempra, Inc. (NASDAQ:CEMP) was downgraded by equities research analysts at Roth Capital from a “buy” rating to a “neutral” rating in a research note issued on Thursday.
CEMP has been the topic of several other reports. Vetr raised Cempra from a “buy” rating to a “strong-buy” rating and set a $4.86 price target on the stock in a research note on Monday, May 1st. Zacks Investment Research cut Cempra from a “buy” rating to a “hold” rating in a research note on Wednesday, May 3rd. Stifel Nicolaus reaffirmed a “hold” rating and issued a $4.00 price target on shares of Cempra in a research note on Thursday. ValuEngine cut Cempra from a “sell” rating to a “strong sell” rating in a research note on Friday, June 2nd. Finally, Jefferies Group LLC reissued a “hold” rating and issued a $3.00 target price on shares of Cempra in a research note on Thursday, May 25th. Four equities research analysts have rated the stock with a sell rating, twelve have given a hold rating, two have given a buy rating and one has assigned a strong buy rating to the company’s stock. Cempra presently has an average rating of “Hold” and a consensus target price of $11.34.
Shares of Cempra (NASDAQ CEMP) traded down 15.07% during trading on Thursday, hitting $3.10. The company had a trading volume of 1,001,729 shares. The firm’s market capitalization is $162.76 million. The company’s 50 day moving average is $4.24 and its 200 day moving average is $3.84. Cempra has a 1-year low of $2.55 and a 1-year high of $26.95.
Cempra (NASDAQ:CEMP) last issued its quarterly earnings results on Wednesday, August 9th. The biotechnology company reported ($0.23) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.32) by $0.09. The company had revenue of $0.86 million for the quarter, compared to analysts’ expectations of $3.58 million. Cempra had a negative return on equity of 56.60% and a negative net margin of 551.45%. The firm’s revenue for the quarter was down 74.9% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.51) earnings per share. Analysts anticipate that Cempra will post ($1.00) earnings per share for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: This piece was originally reported by Ticker Report and is the property of of Ticker Report. If you are reading this piece on another site, it was stolen and republished in violation of U.S. and international copyright & trademark laws. The original version of this piece can be read at https://www.tickerreport.com/banking-finance/2796622/cempra-inc-cemp-rating-reiterated-by-roth-capital.html.
Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Asset Management One Co. Ltd. acquired a new position in shares of Cempra during the first quarter worth about $106,000. Janney Montgomery Scott LLC increased its position in shares of Cempra by 35.6% in the second quarter. Janney Montgomery Scott LLC now owns 25,900 shares of the biotechnology company’s stock worth $119,000 after buying an additional 6,800 shares during the last quarter. UBS Asset Management Americas Inc. acquired a new position in shares of Cempra during the first quarter worth about $140,000. LMR Partners LLP acquired a new position in shares of Cempra during the second quarter worth about $149,000. Finally, State of Wisconsin Investment Board acquired a new position in shares of Cempra during the second quarter worth about $166,000. 52.28% of the stock is currently owned by hedge funds and other institutional investors.
Cempra Company Profile
Cempra, Inc is a clinical-stage pharmaceutical company. The Company focuses on developing differentiated antibiotics for the acute care and community settings to meet medical needs in the treatment of bacterial infectious diseases. Its product, solithromycin (CEM-101), which is a macrolide and fluoroketolide, is being developed in oral capsules, intravenous (IV) and suspension formulations for the treatment of community-acquired bacterial pneumonia (CABP).
Receive News & Ratings for Cempra Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cempra Inc. and related companies with MarketBeat.com's FREE daily email newsletter.